Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2018 · 10-Q
Revenue$5.42M$5.42M+74.5% vs Q3 2017 Net Income$244.93K$244.93KN/M vs Q3 2017 EPS Diluted$0.02$0.02N/M vs Q3 2017 Gross Profit$3,146,416+124.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,078,653N/M Free Cash Flowderived$1,068,115N/M Margins · derivedGross margin58.1%+13.0 pt vs Q3 2017
Operating margin4.1%+24.4 pt vs Q3 2017
Net margin4.5%+24.6 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 5, 2018 · 36 d after period end